A quick peek into the report
Table of Contents
1.1 Market Overview and Ecosystem
1.2 Epidemiological Analysis
1.3 Key Market Trends
1.3.1 Impact Analysis
1.4 Regulatory Landscape
1.5 Pipeline Analysis
1.6 Market Dynamics
1.6.1 Overview
1.6.2 Market Drivers
1.6.3 Market Restraints
1.6.4 Market Opportunities
2.1 North America
2.1.1 Market Dynamics
2.1.2 Market Sizing and Forecast
2.1.3 North America Complicated Urinary Tract Infections Market, by Country ($Million), 2024-2035
2.1.3.1 U.S.
2.2 Europe
2.2.1 Market Dynamics
2.2.2 Market Sizing and Forecast
2.2.3 Europe Complicated Urinary Tract Infections Market, by Country ($Million), 2024-2035
2.2.3.1 U.K.
2.2.3.2 France
2.2.3.3 Germany
2.2.3.4 Italy
2.2.3.5 Spain
2.3 Asia-Pacific
2.3.1 Market Dynamics
2.3.2 Market Sizing and Forecast
2.3.3 Asia-Pacific Complicated Urinary Tract Infections Market, by Country ($Million), 2024-2035
2.3.3.1 Japan
3.1 Competitive Landscape
3.1.1 Mergers and Acquisitions
3.1.2 Partnership, Alliances and Business Expansion
3.1.3 New Offerings
3.1.4 Regulatory Activities
3.1.5 Funding Activities
3.2 Company Profiles
3.2.1 Akero Therapeutics.
3.2.1.1 Overview
3.2.1.2 Top Products / Product Portfolio
3.2.1.3 Top Competitors
3.2.1.4 Target Customers/End-Users
3.2.1.5 Key Personnel
3.2.1.6 Analyst View
3.2.2 Sagimet Biosciences.
3.2.2.1 Overview
3.2.2.2 Top Products / Product Portfolio
3.2.2.3 Top Competitors
3.2.2.4 Target Customers/End-Users
3.2.2.5 Key Personnel
3.2.2.6 Analyst View
3.2.3 Boehringer Ingelheim.
3.2.3.1 Overview
3.2.3.2 Top Products / Product Portfolio
3.2.3.3 Top Competitors
3.2.3.4 Target Customers/End-Users
3.2.3.5 Key Personnel
3.2.3.6 Analyst View
3.2.4 89bio.
3.2.4.1 Overview
3.2.4.2 Top Products / Product Portfolio
3.2.4.3 Top Competitors
3.2.4.4 Target Customers/End-Users
3.2.4.5 Key Personnel
3.2.4.6 Analyst View
3.2.5 Inventiva Pharma.
3.2.5.1 Overview
3.2.5.2 Top Products / Product Portfolio
3.2.5.3 Top Competitors
3.2.5.4 Target Customers/End-Users
3.2.5.5 Key Personnel
3.2.5.6 Analyst View
3.2.6 Galmed Pharmaceuticals.
3.2.6.1 Overview
3.2.6.2 Top Products / Product Portfolio
3.2.6.3 Top Competitors
3.2.6.4 Target Customers/End-Users
3.2.6.5 Key Personnel
3.2.6.6 Analyst View
3.2.7 Novo Nordisk A/S.
3.2.7.1 Overview
3.2.7.2 Top Products / Product Portfolio
3.2.7.3 Top Competitors
3.2.7.4 Target Customers/End-Users
3.2.7.5 Key Personnel
3.2.7.6 Analyst View
3.2.8 Viking Therapeutics.
3.2.8.1 Overview
3.2.8.2 Top Products / Product Portfolio
3.2.8.3 Top Competitors
3.2.8.4 Target Customers/End-Users
3.2.8.5 Key Personnel
3.2.8.6 Analyst View
3.2.9 Hepion Pharmaceuticals.
3.2.9.1 Overview
3.2.9.2 Top Products / Product Portfolio
3.2.9.3 Top Competitors
3.2.9.4 Target Customers/End-Users
3.2.9.5 Key Personnel
3.2.9.6 Analyst View
3.2.10 Pfizer, Inc.
3.2.10.1 Overview
3.2.10.2 Top Products / Product Portfolio
3.2.10.3 Top Competitors
3.2.10.4 Target Customers/End-Users
3.2.10.5 Key Personnel
3.2.10.6 Analyst View
3.2.11 HighTide Biopharma.
3.2.11.1 Overview
3.2.11.2 Top Products / Product Portfolio
3.2.11.3 Top Competitors
3.2.11.4 Target Customers/End-Users
3.2.11.5 Key Personnel
3.2.11.6 Analyst View
3.2.12 Boston Pharmaceuticals.
3.2.12.1 Overview
3.2.12.2 Top Products / Product Portfolio
3.2.12.3 Top Competitors
3.2.12.4 Target Customers/End-Users
3.2.12.5 Key Personnel
3.2.12.6 Analyst View
3.2.13 Rivus Pharmaceuticals.
3.2.13.1 Overview
3.2.13.2 Top Products / Product Portfolio
3.2.13.3 Top Competitors
3.2.13.4 Target Customers/End-Users
3.2.13.5 Key Personnel
3.2.13.6 Analyst View
3.2.14 Lipocine.
3.2.14.1 Overview
3.2.14.2 Top Products / Product Portfolio
3.2.14.3 Top Competitors
3.2.14.4 Target Customers/End-Users
3.2.14.5 Key Personnel
3.2.14.6 Analyst View
3.2.15 Aligos Therapeutics.
3.2.15.1 Overview
3.2.15.2 Top Products / Product Portfolio
3.2.15.3 Top Competitors
3.2.15.4 Target Customers/End-Users
3.2.15.5 Key Personnel
3.2.15.6 Analyst View
3.2.16 MediciNova.
3.2.16.1 Overview
3.2.16.2 Top Products / Product Portfolio
3.2.16.3 Top Competitors
3.2.16.4 Target Customers/End-Users
3.2.16.5 Key Personnel
3.2.16.6 Analyst View
3.2.17 Eli Lilly and Company.
3.2.17.1 Overview
3.2.17.2 Top Products / Product Portfolio
3.2.17.3 Top Competitors
3.2.17.4 Target Customers/End-Users
3.2.17.5 Key Personnel
3.2.17.6 Analyst View
3.2.18 Others
Research Methodology
Table: Market Snapshot
Table: Market Dynamics
Table: Global Complicated Urinary Tract Infections Market (by Region), $Million, 2024-2035
Figure: Complicated Urinary Tract Infections Market (by Scenario), $Million, 2024, 2030, and 2035
Figure: Global Complicated Urinary Tract Infections Market, 2024 and 2035
Figure: Global Complicated Urinary Tract Infections Market Key Trends, Impact Analysis
Figure: North America Complicated Urinary Tract Infections Market, $Million, 2024-2035
Figure: Europe Complicated Urinary Tract Infections Market, $Million, 2024-2035
Figure: Asia-Pacific Complicated Urinary Tract Infections Market, $Million, 2024-2035
Complicated Urinary Tract Infections Market Report Coverage
|
Complicated Urinary Tract Infections Market |
|||
|
Base Year |
2024 |
Market Size in 2024 |
$1.3 Billion |
|
Forecast Period |
2025-2035 |
Value Projection and Estimation by 2035 |
$XX Billion |
|
CAGR During Forecast Period |
XX% |
|
|
Some prominent names established in this market are:
• Akero Therapeutics.
• Sagimet Biosciences.
• Boehringer Ingelheim.
• 89bio.
• Inventiva Pharma.
• Galmed Pharmaceuticals.
• Novo Nordisk A/S.
• Viking Therapeutics.
• Hepion Pharmaceuticals.
• Pfizer, Inc.
• HighTide Biopharma.
• Boston Pharmaceuticals.
• Rivus Pharmaceuticals.
• Lipocine.
• Aligos Therapeutics.
• MediciNova.
• Eli Lilly and Company.
Key Questions Answered in this Report:
• What are the main factors driving the demand for the complicated urinary tract infections market?
• What is the epidemiology of complicated urinary tract infections?
• What are the status of clinical trails in the complicated urinary tract infections market?
• Who are the key players in the complicated urinary tract infections market, and what are their respective market shares?
• What partnerships or collaborations are prominent among stakeholders in the complicated urinary tract infections market?
• What are the strategies adopted by the key companies to gain a competitive edge in the complicated urinary tract infections market?
• What is the futuristic outlook for the complicated urinary tract infections market in terms of growth potential?
• What is the current estimation of the complicated urinary tract infections market, and what growth trajectory is projected from 2025 to 2035?
• Which regions demonstrate the highest adoption rates for the complicated urinary tract infections market, and what factors contribute to their leadership?
Global Complicated Urinary Tract Infections Market, Analysis and Forecast: 2025-2035
Complicated urinary tract infections (cUTIs) are infections of the urinary system that occur in individuals with structural or functional urinary tract abnormalities or in those with underlying conditions that increase the risk of severe or recurrent infection. Unlike uncomplicated UTIs, which typically affect otherwise healthy individuals, cUTIs are often associated with factors such as urinary obstruction, indwelling catheters, diabetes mellitus, immunosuppression, or neurogenic bladder. These infections can involve both the lower and upper urinary tract, potentially leading to serious complications such as pyelonephritis, sepsis, or chronic kidney disease if not promptly treated.
Patients with cUTIs often present with more severe clinical symptoms, including high fever, flank pain, and systemic inflammatory responses. Diagnosis usually requires urine culture and, in many cases, imaging studies to identify anatomical or functional causes. Treatment is more complex and involves targeted antibiotic therapy based on culture results, alongside addressing or correcting the underlying predisposing factors to prevent recurrence.
The global prevalence of complicated urinary tract infections is steadily rising, driven by a combination of factors including increasing rates of diabetes, immunosuppression, urinary tract abnormalities, and widespread use of indwelling medical devices. According to global health estimates, urinary tract infections account for approximately 150 million cases annually worldwide, and a significant proportion of these are complicated cases requiring advanced treatment approaches. The growing patient burden directly drives the demand for more effective and targeted therapeutics, contributing to market expansion.
Additionally, the global elderly population is expanding rapidly, leading to a significant rise in individuals who are more vulnerable to complicated urinary tract infections. Age-related declines in immune function, along with higher rates of chronic conditions such as diabetes and prostate disorders, contribute to this increased susceptibility. In addition, older adults are more likely to require urinary catheters, which further elevates their risk of infection. Catheter-associated urinary tract infections remain a major challenge in hospitals, representing a substantial portion of healthcare-associated infections. This demographic and clinical trend not only broadens the at-risk patient pool but also drives demand for advanced antibiotics, innovative catheter technologies like antimicrobial-coated devices, and specialized infection prevention strategies. As a result, effectively addressing infections in this growing segment presents a significant opportunity for the complicated urinary tract infections market.
Despite these advances, the complicated urinary tract infections market faces several challenges. Antibiotic resistance and treatment limitations are major factors restraining the complicated urinary tract infections market. As bacteria increasingly resist standard antibiotics, treatment options become fewer and less effective, making it harder for clinicians to manage infections successfully. This scenario is similar to trying to fix a leak with limited tools, each failed attempt complicates the situation further. These challenges not only impact patient outcomes but also discourage pharmaceutical companies from investing in new therapies, ultimately slowing market growth and innovation in this critical area.
The global complicated urinary tract infections market is highly competitive, with several leading companies driving innovation and market growth, such as Allecra Therapeutics, Shionogi, Inc., Melinta Therapeutics, Abbvie, and Wockhardt Limited. These companies are at the forefront of developing innovative therapies that are significantly improving patient outcomes in the complicated urinary tract infections (cUTIs) market. Through strategic investments in research and development (R&D), they are introducing novel antibiotics and combination therapies specifically designed to overcome antibiotic resistance and address the urgent need for more effective treatments. By expanding their product portfolios with next-generation antimicrobials and leveraging advanced diagnostic tools to support precision treatment, these industry leaders are reshaping the landscape of cUTI care and driving market growth. Additionally, expanding into emerging markets and strengthening their presence through robust regional distribution networks are key strategies to reach underserved patient populations more effectively. These approaches are enabling companies to solidify their market position and accelerate growth in the competitive and rapidly evolving cUTI treatment arena.
Complicated Urinary Tract Infections Market Segmentation:
Segmentation 1: by Region
• North America
• Europe
• Asia-Pacific
The expansion of the complicated urinary tract infections market is further driven by increasing focus on hospital-acquired infection (HAI) prevention as an opportunity for the cUTI market. Hospitals worldwide are under growing pressure to reduce catheter-associated urinary tract infections (CAUTIs), which account for up to 40% of all healthcare-associated infections. Regulatory policies and financial penalties incentivize hospitals to adopt advanced prevention solutions, such as antimicrobial-coated catheters, rapid diagnostic tools, and infection control technologies. This creates a significant market opportunity for companies developing innovative antibiotics, catheter technologies, and infection monitoring systems, as hospitals are willing to invest in solutions that lower infection rates, improve patient outcomes, and reduce overall treatment costs.
Complicated Urinary Tract Infections Market - A Global and Regional Analysis
Focus on Country and Region - Analysis and Forecast, 2025-2035
Frequently Asked Questions
Major players in the global complicated urinary tract infections market include Akero Therapeutics, Sagimet Biosciences, Inventiva Pharma, Novo Nordisk, Viking Therapeutics, Boston Pharmaceuticals, Aligos Therapeutics, Boehringer Ingelheim, and 89bio, among others.
Trends:
• Strong pipeline of novel antibiotics and treatment approaches
• Increasing focus on hospital-acquired infection (HAI) prevention
Driver:
• Increasing prevalence of complicated urinary tract infections
• Advancements in diagnostic technologies and rapid tests
• Increasing elderly population and catheter-associated infections
• Antibiotic resistance and treatment limitations
• Complex and fragmented regulatory pathways
• Development of non-antibiotic therapies